Abstract:Introduction: Evidence for the efficiency of highly-effective triple-CFTR-modulatory therapy with elexacaftor/tezacaftor/ivacaftor (ETI), either demonstrated in clinical trials or by in vitro testing, is lacking for about 10% of people with cystic fibrosis (pwCF) with rare mutations. Comprehensive assessment of CFTR function can provide critical information on the impact of ETI on CFTR function gains for such rare mutations, lending argument of the prescription of ETI. The mutation c.165-2A>G is a rare acceptor splice mutation that has not yet been functionally characterized. We here describe the functional changes induced by ETI in two brothers who are compound heterozygous for the splice mutations c.273+1G>C and c.165-2A>G. Methods: We assessed the effects of ETI on CFTR function by quantitative pilocarpine iontophoresis (QPIT), nasal potential difference measurements (nPD), intestinal current measurements (ICM), β-adrenergic sweat secretion tests (SST) and multiple breath washout (MBW) prior to and 4 months after the initiation of ETI. Results: Functional CFTR analysis prior to ETI showed no CFTR function in the respiratory and intestinal epithelia and in the sweat gland reabsorptive duct in either brother. In contrast, β-adrenergic stimulated, CFTR-mediated sweat secretion was detectable in the CF range. Under ETI, both brothers continued to exhibit high sweat chloride concentration in QPIT, evidence of low residual CFTR function in the respiratory epithelia, but normalized β-adrenergically stimulated production of primary sweat. Discussion: Our results are the first to demonstrate that the c.165-2A>G/c.273+1G>C mutation genotype permits mutant CFTR protein expression. We showed organ-specific differences in the expression of CFTR and consecutive responses to ETI of the c.165-2A>G/c.273+1G>C CFTR mutants that are probably accomplished by non-canonical CFTR mRNA isoforms. This showcase tells us that the individual response of rare CFTR mutations to highly-effective CFTR modulation cannot be predicted from assays in standard cell cultures, but requires the personalized multi-organ assessment by CFTR biomarkers.

Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia

S2599 A Rare Cystic Fibrosis Gene Mutation Associated With GI Manifestations in the Absence of Pulmonary Disease

F1099L-CFTR (c.3297C>G) has Impaired Channel Function and Associates with Mild Disease Phenotypes in Two Pediatric Patients

A Rare Case of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene Mutation on Exon 8 in a Patient Presenting With Recurrent Infections and Failure to Thrive

Complete CFTR Gene Sequencing in 5,058 Individuals with Cystic Fibrosis Informs Variant-Specific Treatment.

Genomic Rearrangements in the Cftr Gene: Extensive Allelic Heterogeneity and Diverse Mutational Mechanisms

In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis

Genetic Modifiers of Cystic Fibrosis Lung Disease Severity

C.753_754delag, a Novel CFTR Mutation Found in a Chinese Patient with Cystic Fibrosis: A Case Report and Review of the Literature

Cystic fibrosis management in pediatric population—from clinical features to personalized therapy

Diagnosis of cystic fibrosis: a high heterogeneity of symptoms and genotypes in a Brazil population

Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians

The Clinical Biology of Cystic Fibrosis Transmembrane Regulator Protein: Its Role and Function in Extrapulmonary Disease

Functional Consequences of CFTR Interactions in Cystic Fibrosis

Accounting for Population Structure in Genetic Studies of Cystic Fibrosis.

Differential effects of ELX/TEZ/IVA on organ-specific CFTR function in two patients with the rare CFTR splice mutations c.273+1G>A and c.165-2A>G

Exploring Turkey's mosaic of novel variants and complex alleles in cystic fibrosis genetics

A bibliometric analysis of cystic fibrosis transmembrane conductance regulators

Compound heterozygous CFTR variants (Q1352H and 5T; TG13) in a Chinese patient with cystic fibrosis

CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation

Current landscape of cystic fibrosis gene therapy